Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, the clinical- …